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6/j.bAfter double-cord blood transplantation, long-term hematopoietic dominance of a single-cord blood donor
graft is established in themajority of patients; however, themechanismbehind this observation remains largely
unknown. Beginning at day 7 posttransplantation, we prospectively measured weekly lineage-specific periph-
eral blood donor chimerisms in patients undergoingmyeloablative double-cord blood transplantation to eval-
uate whether the degree of early donor contribution to specific lineage(s) would predict the long-term
engrafting unit. Our results demonstrate that the donor unit with higher CD3 chimerism at day 7 became
the dominant engrafting unit in 26 of 31 evaluable patients (P 5 .0002) and in 34 of 34 evaluable patients at
day 14 (P\.0001). Similarly, higher donor unit CD33 chimerism was associated with dominant engraftment
in 8 of 8 (day 7) and in 31 of 32 (day 14) evaluable patients. No statistically significant correlation between the
dominant unit and order of infusion, infused total nucleated cells, CD34, or CD3 cell doses, unit viability, or
HLAdisparitywas observed. The correlation of higher early posttransplantation donorCD3peripheral blood
chimerism with the dominant unit suggests a rapid immune-mediated response as a primary mechanism of
action for long-term single-donor dominance. This finding may have clinical implications for early selection
of the winning unit after double-cord blood transplantation and for novel cord blood manipulation strategies.
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Given the rapid availability and less stringent HLA
matching requirements, cord blood (CB) stem cells are
increasingly being used as a donor for hematopoietic
cell transplantation, especially when a conventional
bone marrow or peripheral blood stem cell donor can-
not be identified. In order to overcome the limitation
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double-unit CBT (dCBT) is commonly performed
for adult and larger adolescent patients [1]. Only 1
CB unit typically persists as the engrafting donor re-
sponsible for long-term hematopoiesis after myeloa-
blative dCBT; however, no studies have reproducibly
identified pre- or early posttransplantation factors
that predict which unit will predominate.
Potential variables contributing to donor domi-
nance that have previously been evaluated include
cryopreserved and infused total nucleated cell (TNC)
and CD341 cell doses, infused CD31 cell doses, over-
all viability, degree of HLA or gender matching, ABO
typing, and order of unit infusion, all without defini-
tive or reproducible correlation [2-5]. Although
Scaradavou et al. [6] suggested that units with low
CD341 viability are less likely to engraft in the
dCBT setting, Ramirez et al. [7] identified CD31
cell dose as the most significant predictor of unit
predominance among preinfusion variables. A recent
analysis by Avery et al. [8] found that higher infused
CD31 cell doses and percentage CD341 cell viability
were associated with unit dominance. It has also
been postulated that graft-versus-graft immune inter-
actions contribute to the emergence of single-donor
dominance [9-11].1243
1244 Biol Blood Marrow Transplant 18:1243-1249, 2012L. F. Newell et al.To further investigate the kinetics of single-donor
dominance, we evaluated peripheral blood (PB) donor
chimerisms in specific cell subsets in the immediate
posttransplantation period. Our findings indicate
that the CB unit with higher CD3 chimerism very
early posttransplantation is much more likely to be-
come the long-term engrafting unit after myeloabla-
tive dCBT.PATIENTS AND METHODS
Patient and Donor Characteristics
Between October 2007 and May 2011, 46 consecu-
tive patients receivedmyeloablativeCB transplantations
on protocol at the Fred Hutchinson Cancer Research
Center that included the routine collection of day 7
and 14 posttransplantation PB chimerisms. Six of these
patients received single-unit CBT and were thus ex-
cluded from further analysis. Of the remaining 40 pa-
tients, 5 patients were excluded because of primary
graft failure (N5 2) and disease relapse before engraft-
ment (N5 2), and 1 death early posttransplantation (day
6), leaving 35 evaluable patients. All CBT recipients or
their parents signed informed consent before transplan-
tation. All patients received unrelated donor CB grafts,
which were 4 of 6 to 6 to 6 matched to the recipient at
HLA-A, -B, and -DRB1 antigens, with 37 units (53%)
being 4 of 6 matched, 23 units (33%) 5 of 6 matched,
and 10 units (14%) 6 of 6matched.HLA typingwas per-
formed at the antigen level forHLA-A and -B, and high-
resolution HLA typing was performed for HLA-DRB1
alleles. The individual CB units were at least 3 of 6-
HLA-A, -B, and -DRB1 matched to each other, and
each contained a minimum of 1.5  107 TNC/kg. All
CB units were thawed and washed per institutional
guidelines before infusion and TNC viability was as-
sessed by 7-amino-actinomycin (Beckman Coulter,
Fullerton,CA)dye exclusion. InfusedTNCdosesperki-
logramwere derived from postthaw cell counts, whereas
CD341 and CD31 cell doses per kilogram were calcu-
lated from flow cytometry analyses of postwash samples.
Conditioning Regimens and Graft-versus-Host
Disease Prophylaxis
Patients received myeloablative preparative regi-
mens with either high-dose total-body irradiation
(TBI)-based conditioning consisting of 1320 cGy
TBI, Fludarabine 75 mg/m2, and Cyclophosphamide
120 mg/kg, or low-dose TBI-based conditioning with
200 cGy TBI, Treosulfan 42 mg/m2, and Fludarabine
150 mg/m2. All patients received cyclosporine plus
mycophenolate mofetil for prevention of acute graft-
versus-hostdisease (GVHD).Granulocyte-colony stim-
ulating factor was given posttransplantation until stable
absolute neutrophil (ANC) recovery to .2.5  109/L
and then as needed to maintain an ANC.1.0 109/L.Donor Chimerism Analysis
PB was obtained weekly from days 7 to 28, and
then as possible at days 42, 56, 80, 180, 365, and 2 years
posttransplantation. The blood was flow sorted in the
clinical hematopathology laboratory of the Seattle
Cancer Care Alliance into defined lineage subsets,
consisting of CD31 (T cells), CD331 (granulocytes),
CD141 (monocytes), and CD561 (natural killer) cell
fractions as previously described [12]. Postsort purity
was routinely monitored as per standard operating
procedures and was uniformly .98%. Samples con-
taining\100 total sorted cells were considered insuf-
ficient for further analysis. DNA chimerism analysis
was performed by amplified fragment length polymor-
phism (detection sensitivity 1% to 5%, range of accu-
racy 65%) [13]. Single-donor dominance was defined
as 1 unit serially contributing.70% of the donor chi-
merism in all cell fractions, or as the only CB donor
present. Loss of host contribution was defined as the
presence of \5% of recipient hematopoiesis in the
CD3 cell fraction.
Statistical Analysis
An exact two-sided one-sample test of the null hy-
pothesis that a binomial proportion is equal to 0.5 was
used to test the association of concordance of higher
day 7 or day 14 chimerism or infused cell subset dose
with unit dominance, because, if there were no corre-
lation between the unit with higher chimerism and it
becoming the predominant unit, the probability of
such an event would be 0.5. Similarly, a two-sided
one-sample t-test was also used to test the null hypoth-
esis that the mean differences in chimerism or cell dose
between dominant and losing units were equal to zero.
Days to engraftment, days to establishment of single-
donor dominance, and days to disappearance of host
were compared among conditioning groups using the
2-sample t-test or the nonparametric Wilcoxon rank-
sum test among patients who achieved the relevant
endpoint. Overall survival was estimated using the
Kaplan-Meier method, and relapse was summarized
using a cumulative incidence estimate, with death
without relapse a competing risk for relapse.RESULTS
Analysis of Donor Chimerism at Days 7 and 14
Posttransplantation
Beginning onOctober 10, 2007, all patients under-
goingmyeloablative dCBTonan institutional protocol
had PB drawn weekly in the first month posttransplan-
tation to determine the contributionof the 2CBdonors
as well as the host to circulating myeloid and lymphoid
lineage subsets. Patient, donor, and transplantation
characteristics of the cohort are summarized in
Table 1. Cohort Characteristics
Patient age, median years (range) 33.3 (6.7-63.3)
Gender, no. (%)
Female 17 (49)
Male 18 (51)
Disease, no. (%)
AML 14 (40)
ALL 11 (31)
MDS/MPD 7 (20)
Other 3 (9)
Transplantation type, no. (%)
FLU/CY/TBI 1320 cGya 17 (49)
TREO/FLU/TBI 200 cGyb 18 (51)
GVHD prophylaxis, no. (%)
Cyclosporine/mycophenolate 35 (100)
Median recipient weight in kg (range)
HLA disparity, no. (%)c 75.3 (22.5-114.4)
4/6 21 (60)
5/6 11 (31)
6/6 3 (9)
Median TNC  107/kg (range)d 4.6 (3.6-10.2)
Median CD34+  106/kg (range)d 0.18 (0.08-0.66)
Median CD3+  106/kg (range)d 11.0 (6.0-28.2)
Viability % (range)d 73 (60-87)
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leuke-
mia; MDS/MPD, myelodysplastic/myeloproliferative diseases; FLU,
fludarabine; CY, cytoxan; TREO, treosulfan; kg, kilogram.
aFludarabine 75 mg/m2, Cytoxan 120 mg/kg, TBI 1320 cGy.
bTreosulfan 42 gm/m2, Fludarabine 150 mg/m2, TBI 200 cGy.
cHLA matching reflects the lowest HLA match of the 2 units.
dMedian TNC, CD34+, CD3+, and viability of 2 combined units.
Table 2. Cohort Analysis
Chimerisms
Mean Difference (95% CI, P value)a
Patients with
Concordanceb
Day 7 CD3
chimerism
16.1 (7.1-25.0, P 5 .001) 26/31, P 5 .0002
Day 7 CD33
chimerism
23.1 (7.4-38.9, P 5 .02) 8/8, P 5 .008
Day 7 CD14
chimerism
20.9 (230.0-28.1, P 5 .95) 9/16, P 5 .80
Day 7 CD56
chimerism
11.1 (27.4-29.5, P 5 .26) 12/19, P 5 .36
Day 14 CD3
chimerism
80.1 (70.0-90.3, P < .0001) 34/34, P < .0001
Day 14 CD33
chimerism
69.3 (57.6-80.9, P < .0001) 31/32, P < .0001
Day 14 CD14
chimerism
82.5 (71.8-93.2, P < .0001) 32/33, P < .0001
Day 14 CD56
chimerism
80.1 (68.0-92.3, P < .0001) 32/33, P < .0001
Preinfusion Variables
Mean Difference (95% CI, P value)a
Patients with
Concordanceb
Infused
TNC  107/kg
0.0022 (20.0015-0.0059, P 5 .25) 19/33, P 5 .49
Infused
CD34+  106/kg
0.0287 (20.0058-0.0633, P 5 .11) 21/33, P 5 .16
Infused
CD3+  106/kg
0.6638 (20.7249-2.052, P 5 .33) 20/33, P 5 .29
Viability 2.06 (22.75-6.87, P 5 .41) 19/35, P 5 .74
HLA disparity NA 4/9, P 5 1.0c
Order of infusion NA 19/35, P 5 .74d
Gender match NA 4/15, P 5 .12e
CI indicates confidence interval.
aMean of the difference between winning and losing units.
bNumber of patients where larger chimerism value led to winning unit/
total number of patients evaluable.
cConcordance between better HLA match and winning unit, when
degree of CB donor-patient HLA match differs among the 2 units.
dConcordance between first unit infused and winning unit.
eConcordance between patient gender and gender of winning unit, when
unit 1 gender differs from unit 2 gender.
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were not evaluable for some patients because of limited
numbers of circulating cells; therefore, we first ana-
lyzed lineage-sortedPBchimerismsatday14as ameans
to predict the long-term engrafting unit. Even at this
time point, the median white blood cell, absolute neu-
trophil, and absolute lymphocyte countswere#0.2/mL
(range, 0-3900/mL), 0 (range, 0-3000), and 0 (range, 0-
2184). However, despite such low blood counts, of the
35 cohort patients, 34 had sufficient numbers of circu-
lating CD31 cells for cell sorting and chimerism deter-
mination. In all 34 evaluable patients, the unit with
higher donor CD3 chimerism on day 14 already was
or subsequently became the dominant engrafting unit
(P\ .0001). Similar results were also observed in the
day 14 CD331, CD141, and CD561 cell fractions,
where the CB donor with the higher chimerism corre-
lated with the ultimately dominant engrafting unit (31
of 32 for CD33, and 32 of 33 for both CD14 andCD56
chimerisms; P\ .0001 for all groups) (Table 2).
Given the positive correlation between higher do-
nor chimerism and the long-term engrafting unit in all
cell subsets at day 14, we then looked to see if the CB
unit with higher chimerism in specific cell subset(s)
was also predictive of the long-term winning unit as
early as day 7. There were frequently too few circulat-
ing CD561, CD141, and CD331 cells for analysis
at day 7; however, in 31 of 35 patients, there were
sufficient circulating CD31 cells for sorting and
assessment of donor chimerisms. Notably, in 26 of
these 31 patients, the unit with higher donor CD3chimerism on day 7 became the dominant engrafting
unit (P 5 .0002) (Table 2 and Figure 1). Moreover,
the mean percent difference in day 7 chimerism be-
tween what became the dominant engrafting unit and
the nondominant unit was 16% (P 5 .001) (Table 2).
In contrast to the early detection of CD31 cells,
only 16 of 35 and 19 of 35 patients had sufficient num-
bers of circulating CD141 and CD561 cells, respec-
tively, for chimerism analysis at day 7. Among these
patients, there was no statistically significant concor-
dance between the unit with higher CD14 or CD56
chimerism and the long-term engrafting unit (9 of
16; P 5 .80 and 12 of 19; P 5 .36, respectively), nor
was the mean difference in chimerism statistically sig-
nificantly different from zero (Table 2). An even
smaller subset of patients (n 5 8) had sufficient cell
counts to evaluate the donor contribution to CD33
at this time point. In all 8 of these patients, the unit
with the higher CD33 chimerism later became the
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Figure 1. CD3 and CD33 chimerisms: at day 7, 26 of 31 patients showed concordance between higher donor CD3 chimerism and the long-term
engrafting unit; at day 14, 34 of 34 patients showed concordance (top row). Higher-donor CD33 chimerism showed concordance with the winning
unit in 8 of 8 patients at day 7 and in 31 of 32 patients at day 14 (bottom row). Patients with losing unit chimerism of 0 were recorded as ratio of
winning/losing unit .50.
1246 Biol Blood Marrow Transplant 18:1243-1249, 2012L. F. Newell et al.dominant unit (P 5 .008) (Table 2 and Figure 1). In
addition, the mean difference in chimerism between
winning and losing units in these 8 patients was 23%
(P 5 .02) (Table 2). In contrast to previous reports,
we found no statistically significant correlation be-
tween the long-term dominant unit and infused
TNC, CD341, or CD31 cell doses, unit viability,
HLA disparity, or order of infusion (Table 2).Time to Single-Donor Dominance and
Contribution of Host Chimerisms
Of the 35 cohort patients, all but 3 patients ulti-
mately demonstrated disappearance of the nondomi-
nant unit below the detection limit of the DNA
chimerism assay, occurring at a median of 21 days.
Single-donor dominance was established by day 14 in
38% of the cohort patients and by day 28 in an addi-
tional 47%, with only 15% of patients converting to
a single donor beyond day 28. Among the 3 patients
with persistent contribution of both CB units, all
ultimately developed .70% chimerisms from the
dominant unit (.95% at day 361, .70% at day 163,
and.90% at day 93, in all cell fractions). In this small
cohort of patients, the time to single-donor dominance
was not correlatedwith other transplantation outcomes,including time to neutrophil or platelet recovery nor
the development or intensity of acute GVHD.
The degree of host contribution to total CD3 chi-
merism at day 7 was not predictive of single-donor
dominance. In the 26 patients with concordance be-
tween higher chimerism and winning unit, the average
host contribution to CD3 chimerism was 36% com-
pared with 46% among the 5 patients without concor-
dance (P 5 .39) (Figure 2). Last, the median time to
disappearance of host contribution to CD3 among
patients receiving high-dose TBI-based conditioning
was 14 days and among patients receiving low-dose
TBI-based conditioning was 28 days.Transplantation Outcomes
Thirty-five patients with a median age of 33.3 years
were evaluable for analysis and underwent dCBT for
hematologic malignancies. Neutrophil engraftment,
defined as an absolute neutrophil count (ANC) $500/
mL for 3 consecutive days, occurred in 33 of the 35 pa-
tients (94%) at a median of 25 days (range, 13-89 days).
The other 2 patients had establishment of single-donor
dominance per PB chimerism analyses but died before
achieving an ANC above 500. Platelet engraftment
within the first 100 days after transplantation, defined
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Figure 2. Contribution of host and donor cord blood units to day 7 and 14 CD3 chimerism.
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without transfusion for 7 consecutive days, occurred
in 23 of the 35 patients (65%) at a median of 36 days
(range, 24-72 days). There was no statistically signifi-
cant difference in the time to neutrophil engraftment
among patients receiving high-dose TBI-based condi-
tioning versus Treosulfan-based conditioning, occur-
ring at a median of 25 days (range, 14-45) and 23 days
(range, 13-89), respectively (P5 .64).DISCUSSION
After dCBT, only 1 of the 2 CB units typically per-
sists for long-term hematopoiesis. Although develop-
ment of single-donor dominance has been well
described, prior studies have not identified a reliable
method of predicting which will be the long-term en-
grafting unit, nor has the mechanism of single-donor
dominance been fully elucidated. Herein, we show
that individual CB donor contribution to CD3 chime-
rism, as measured by PB lineage-specific amplified
fragment length polymorphism analysis, is very pre-
dictive of the dominant engrafting unit as early as
days 7 and 14 after myeloablative dCBT.
Prior publications and clinical experience have both
shown a critical role for T cells in facilitating/enhancing engraftment after hematopoietic cell trans-
plantation, with higher rates of graft failure seen after
T cell-depleted allografts [14,15]. In immunodeficient
murine xenograft models, single-donor dominance
was found only after dCBT of total mononuclear cells;
dominance was not established if purified CD341 frac-
tions or lineage-depleted cells from the same units were
used, suggesting that the CD34-negative population(s)
is critical to the emergence of a dominant single unit
[16-18]. Additional evidence of an in vivo immune-
mediated mechanism for single-donor dominance was
described by Gutman et al. [10]. Among patients
developing single-donor dominance after ablative
dCBT, effector T cells (CD81CD45RO1/2CCR72)
derived from the engrafting unit were detected as early
as day 14 in the peripheral blood of 9 out of 10 patients.
A significant subset of these effector CD81T cells pro-
duced interferon-g in a mixed lymphocyte reaction to
cells derived from the nonengrafting unit, supporting
the hypothesis that single-donor dominance is
immune-mediated and likely driven by CD34-negative
accessory cells in the graft [10].
Data regarding the association of donor CB charac-
teristics at the timeof infusion (TNC,CD341 cell doses,
etc) with subsequent single-donor dominance have not
been consistent. Avery et al. [8] recently described an
1248 Biol Blood Marrow Transplant 18:1243-1249, 2012L. F. Newell et al.association between CD31 cell doses and CD341 cell
viability and single-donor dominance. Dominant units
were more likely to be characterized by higher-infused
CD31 cell doses and CD341 cell viability $75%. In
contrast, earlier series reported a lackof reproducible as-
sociation between infused CD31 dose and unit domi-
nance. Majhail et al. [19] noted no difference between
predominant and nonsustained units in terms ofmedian
infusedTNC,CD341, andCD31 cell doses but did de-
scribe a higher granulocyte-macrophage colony-form-
ing unit content in the predominant unit. In part, these
differentfindingsmay reflect challenges in accurately as-
sessing cell subsets in the postthaw CB products. Our
analysis of preinfusion variables showed no statistically
significant correlation with the dominant donor in this
relatively small series; however, further evaluation with
a larger cohort size is ongoing [20].
PB chimerism obtained at day 7 postmyeloablative
transplantation can be challenging, not only from the
perspective of the cost of performing this study but
primarily because of the difficulty in performing this
assay with low cell numbers. However, in our experi-
ence, analysis of day 7 CD3 chimerism is achievable in
the majority of cases, perhaps reflecting the infusion
of T cells contained within the 2 grafts. In contrast,
CD33 chimerism is frequently unavailable at this time
point, calling into question its utility as a stand-alone
predictor of donor dominance. CD33 chimerism data
were available at day 7 in only 8 of our 35 evaluable
patients. Importantly, in 7 of these 8 patients, day 7
CD3 chimerism also correlated to the winning unit,
suggesting that the combination of both CD3 and
CD33 chimerism together, when available, may better
predict the winning unit.
The ability to predict the dominant CB unit very
early posttransplantation might be useful clinically,
as delayed hematopoietic recovery and immune recon-
stitution after dCBT remain ongoing limitations to the
more widespread adoption of CB as a stem cell donor
source. In addition, lack of available donor lympho-
cytes for potential adoptive immunotherapies to im-
prove engraftment, immune reconstitution, or to
treat relapse is problematic. New strategies being in-
vestigated include infusions of ex vivo expanded antivi-
ral T cells [21] and the generation of cytokine-induced
killer [22] or natural killer cells [22,23], typically
derived from a small aliquot of residual cells obtained
at the time of CB infusion. Reliable prediction of the
dominant unit by day 7 after dCBT would allow
early selection of the appropriate starting cells to be
further manipulated in the development of adoptive
immunotherapies, or in potential manipulations to
augment engraftment of the desired CB donor.
The mechanism of single-donor dominance is
likely to be multifactorial, involving intrinsic features
of the CB units such as the homing properties and pro-
liferative potential of the stem cells, graft-graft interac-tions mediated by T cell interactions among others, as
well as host-graft interactions [24]. To our knowledge,
this study is the first to show a concordance between
lineage-specific donor PB chimerism, specifically, the
CD31 T cell subset, measured as early as day 7 after
myeloablative dCBT and subsequent emergence of a
dominant long-term engrafting unit. Additional studies
are necessary to further evaluate the hypothesis that
immune-mediated graft-graft interactions contribute
to single-donor dominance early posttransplantation,
and the potential role of the CD34-negative cell pop-
ulation in the emergence of single-donor engraftment.
Importantly, early prediction of the long-term engraft-
ing unit after dCBT may allow for more rational CB
manipulation strategies and for the development of
novel immunotherapeutic approaches to improve
clinical outcomes.ACKNOWLEDGMENTS
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